Temozolomide-Induced Myelodysplasia

Table 1

Estimated CDT for selected potentially leukemogenic agents.

Compound	Activity	CDT (mg/sq m)	Latency to MDS/AML (yrs)
Temozolamide	alkylating agent	18–20,000	0.75–3
Cyclophosphamide	alkylating agent	8–10,000	2–10
Alkeran	alkylating agent	80	2–10
Mechlorethamine	alkylating agent	60	2–10
Etoposide	topo II inhibitor	2,000	1–4
Mitoxantrone	topo II inhibitor	60	0.50–5
Benzene	unknown	46,000	2–10